Objectives: For English, the validated part of Psychedelic Experience Scale (PES48) is a four-factor structure called the Mystical Experience Questionnaire (MEQ30). The other validated part of the PES48 consists of four more factors: two more mystical factors (paradoxicality and connectedness, which together with the MEQ30 form the MEQ40), and two more non-m...
Introduction: Psilocybin therapy has demonstrated efficacy for cancer-related anxiety and depression, but resource-intensive individual treatment models raise important questions for psychedelic public health about equitable access and scalability. In our prior Phase 1/2 study of group retreat psilocybin therapy for patients with metastatic cancer, we observ...
The purpose of the present study is to evaluate the feasibility, initial signals of efficacy, and potential mechanisms of action of "microdoses" of psilocybin (i.e., low doses of psilocybin that are not believed to produce mystical-type, transcendent, hallucinogenic, or other overtly salient subjective effects that limit functionality) in the treatment of mo...
The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia. Investigators will assess the impact of psilocybin-facilitated treatment on pain, fatigue, and other fibromyalgia symptoms, in addition to the level of functioning and quality of life. Investigators will also evaluate potential me...
The goal of this clinical trial is to learn if psilocybin, given with psychological support, is safe and helps treat anorexia nervosa in young adults. Anorexia nervosa is a serious eating disorder that currently has no approved medicine. Psilocybin is a psychedelic substance that may help the brain form new connections, which could make it easier for people ...
Rationale: Ego-dissolution represents a key therapeutic mechanism in psychedelic-assisted therapy, yet current measurement approaches may inadequately capture its multidimensional nature. Objective: To develop and validate the Multidimensional Ego-Dissolution Assessment (MEDA) and examine substance-specific patterns across classical psychedelics. Methods: It...
Background: Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have been shown to predict the clinical effects of psilocybin treatment in depression, anxiety, and addiction. However, no studies have examined whether acute subjective experiences predict treatment response in obsess...
Abstract Large language models (LLMs) are increasingly consulted by individuals for support during psychedelic experiences ("trip sitting"), yet no framework exists to evaluate whether these models can accurately simulate or safely respond to altered states of consciousness. We aimed to determine if LLMs can be induced to generate narratives resembling human...
Objective: Emerging evidence suggests that mystical experiences mediate the therapeutic effects of psychedelic-assisted therapy. The current study examines associations between mystical experiences and components of “set” (positive mindset, participant intentions, and spirituality) and “setting” (perceived positivity of the dosing environment) in the context...
OBJECTIVE: To compare changes in depression, anxiety, and suicidality symptoms after a single 25 mg oral dose of psilocybin between treatment-resistant depression participants not on antidepressants at screening to participants that discontinued antidepressant medications leading up to receiving psilocybin-assisted psychotherapy (PAP). METHODS: Participants ...
IntroductionThe intensity of the psychedelic experience has been hypothesized as the main predictor of response to a psychedelic treatment. This study aimed to investigate factors that may be associated with the intensity of mystical experiences during naturalistic psychedelic use.MethodsThe data of this comprehensive sample were aggregated from four previou...
RATIONALE: Psychedelic-assisted therapy is increasingly applied within mental health treatment. OBJECTIVES: This study focused on factors moderating changes in the acute and long-term effects of an individual psilocybin-assisted program on depression, anxiety, PTSD and personality structures by including demographic factors, subjective experience and degree ...
Background: Psilocybin can produce long-term changes in personality, personal values, and behavior. Although psilocybin-assisted therapy (PAT) is being actively studied for various psychiatric conditions, its effects on personal values in patients with alcohol use disorder (AUD) remain unexplored. This study examined the effects of PAT on personal values in ...
Objective: The aesthetic qualities of psychedelic experiences have long been documented, but their specific contribution to therapeutic outcomes remains unexplored. This study investigates the role of psychedelic-induced aesthetic experiences in predicting positive psychological outcomes. Methods: Using a cross-sectional naturalistic survey, participants who...
Objective: The aesthetic qualities of psychedelic experiences have long been documented, but their specific contribution to therapeutic outcomes remains unexplored. This study investigates the role of psychedelic-induced aesthetic experiences in predicting positive psychological outcomes. Methods: Using a cross-sectional naturalistic survey, participants who...
Objective: The aesthetic qualities of psychedelic experiences have long been documented, but their specific contribution to therapeutic outcomes remains unexplored. This study investigates the role of psychedelic-induced aesthetic experiences in predicting positive psychological outcomes. Methods: Using a cross-sectional naturalistic survey, participants who...
BACKGROUND: Research with the Psychedelic Experience Questionnaire/Scale (PES) focuses on questions relating to mystical experience (Mystical Experience Questionnaire (MEQ)). The psychometric potential of the non-MEQ items of the PES remains largely unexplored. AIMS: We investigated whether the PES also yields subscales besides the MEQ30 subscales. METHODS: ...
Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and paranoia). These challenging experiences contribute to hesitancy toward psychedelic-assisted psychotherapy among health care providers and patients. Co-use of 3,4-Methylenedioxy methamphetamine (MDMA) with psilocybin/LSD anec...
Flotation-Reduced Environmental Stimulation Therapy (REST) and mindfulness meditation (MM) are known to induce altered states of consciousness (ASC) and self-consciousness. In this study, we use a phenomenological and predictive processing (PP) framework to compare the interventions alongside the psychedelic experience. Ego-dissolution scores were greater th...
Flotation-Reduced Environmental Stimulation Therapy (REST) and mindfulness meditation (MM) are known to induce altered states of consciousness (ASC) and self-consciousness. In this study, we use a phenomenological and predictive processing (PP) framework to compare the interventions alongside the psychedelic experience. Ego-dissolution scores were greater th...
